<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361878</url>
  </required_header>
  <id_info>
    <org_study_id>2013DM06</org_study_id>
    <nct_id>NCT03361878</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Metformin Intolerance</brief_title>
  <acronym>POMI</acronym>
  <official_title>Pharmacokinetics of Metformin Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum MÃ¼nchen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic study of metformin intolerance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pharmacokinetic study recruited white European individuals with type 2 diabetes, who had
      previously been exposed to metformin and met the criteria for tolerance or intolerance.
      Intolerance was defined as previous exposure to metformin (maximum of 1000mg once daily for
      up to 8 weeks) but discontinued treatment with patient reported or documentation of
      gastrointestinal upset, leading to discontinuation (Criterion 1). Alternatively, intolerance
      was defined as inability to increase metformin dose above 500mg without experiencing
      gastrointestinal side-effects, despite having an HbA1c &gt;53mmol/mol (Criterion 2). Tolerant
      individuals were defined as those taking 2000mg metformin daily in divided doses, with no
      side effects. Ten tolerant and ten intolerant individuals were recruited.

      Participants gave written consent. They attended the research centre fasted from midnight. A
      baseline blood test was taken before a single dose of oral metformin was administered at
      0900, with further bloods taken at 11 time points over the following 24 hours. A 24 hour
      urine collection was completed.

      Blood samples were analysed for plasma metformin, and serum lactate concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2014</start_date>
  <completion_date type="Actual">May 5, 2016</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms - metformin tolerant and metformin intolerant. All participants given single dose of metformin.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin AUC</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the metformin concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in lactate concentration (incremental AUC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Metformin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Metformin Tolerant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Intolerant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Single dose of 500mg oral metformin</description>
    <arm_group_label>Metformin Tolerant</arm_group_label>
    <arm_group_label>Metformin Intolerant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  White European

          -  Type 2 diabetes

          -  Meet criteria for tolerance or intolerance as described

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) &lt;60

          -  Cognitive impairment

          -  Pregnancy

          -  Concurrent treatment with: acarbose, cephalexin, cimetidine, pyrimethamine, or
             tyrosine kinase inhibitors

          -  History of gastric bypass

          -  Evidence of slowed gastric or intestinal motility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura McCreight, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NHS Tayside</investigator_affiliation>
    <investigator_full_name>Laura McCreight</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Intolerance</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Participants have been consented for data sharing. Only anonymised data would be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

